ResearchKit is already helping medical researchers make breakthrough discoveries in areas like Parkinson's disease, autism, or cardiovascular disease. The next goal of this open source software is to use ResearchKit to study hepatitis C, which comes from a virus about which little is known at the moment but which affects many patients. It is a disease that has a great impact, but researchers still do not understand some effects of the virus itself and of the drugs used to treat it in everyday life.
Boston Children's Hospital has created a new ResearchKit app called CTracker (something like "C follow-up") that allows patients who have hepatitis C keep track of the virus answering some basic questions, describing some facts and describing the activity levels. According to Dr. Ken Mandl, C Tracker will allow researchers to understand how hepatitis C patients live in the real world, allowing them to see the impact of hepatitis C in ways never seen before.
In a ResearchKit blog post detailing the app, Mandl says the most important innovation is a new backend called C3-PRO (not to be confused with C3-PO, who is now in theaters) which is being made available to the research community for use with other ResearchKit applications.
C3-PRO (Consent, Contact and Community framework for Patient Reported Outcomes) connects any ResearchKit application with an IT infrastructure called i2b2 that is widely used in clinical research. C Tracker adds users while keeping their data completely anonymous. In future versions, the hospital plans to prescribe the application to study other patients so that their data can connect to i2b2, thereby hoping to collect new data.
It seems to me that you are mistaking the virus, Hepatitis C already has a cure with the famous drug called Sovaldi, let's see if for once and for all we contrast the information before publishing it, which is not the first time that you screw up in this way .
And what did I say wrong? If you want a summary, ResearchKit will be used to study hepatitis C.
Reading is more important in any case.
The article talks about improving Hepatitis C treatment, not creating a cure.
If hepatitis C is curable, in October 2014 the combination of Sofosbuvir and Ledipasvir was marketed in Europe, under the trade name Harvoni.
We will have if we reread the news, because it says that researchkit will be used to study hepatitis C ... if there is already a patented drug, which costs 80000 dollars in the US and in Europe about 60000 euros, so "it already has a cure" is the only thing for the rich, many developed countries cannot afford that ... what they do is take another similar drug but that is a little more dangerous ...
Honestly ... patent whores ... (money is worth more than human lives ... but what is going to do, human beings are greedy by nature ...)
Greetings and merry christmas!